Terms: = Small Cell Lung Cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
3608 results:
1. Deep learning to estimate response of concurrent chemoradiotherapy in non-small-cell lung carcinoma.
Peng J; Zhang X; Hu Y; He T; Huang J; Zhao M; Meng J
J Transl Med; 2024 Oct; 22(1):896. PubMed ID: 39367461
[TBL] [Abstract] [Full Text] [Related]
2. Genetic Profiling of Non-small cell lung cancer in Moroccan Patients by Targeted Next-Generation Sequencing.
El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Boustany Y; Benmokhtar S; Lamrani Alaoui H; El Annaz H; Abi R; Tagajdid MR; El Kochri S; El Mchichi B; Bouaiti EA; Lahlou IA; El Hassani RA; Ennibi K
Technol Cancer Res Treat; 2024; 23():15330338241288907. PubMed ID: 39363851
[TBL] [Abstract] [Full Text] [Related]
3. Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients.
Gristina V; Russo TDB; Barraco N; Gottardo A; Pepe F; Russo G; Fulfaro F; Incorvaia L; Badalamenti G; Troncone G; Malapelle U; Russo A; Bazan V; Galvano A
Sci Rep; 2024 Sep; 14(1):22141. PubMed ID: 39333636
[TBL] [Abstract] [Full Text] [Related]
4. Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small cell lung cancer in China.
Lu S; Shen L; Wang Q; Chen H; Zhao Y; Li Y; Segall G; Khanal M; Zhang X; Ding D; Shao J; Pang L
Adv Ther; 2024 Nov; 41(11):4248-4265. PubMed ID: 39316291
[TBL] [Abstract] [Full Text] [Related]
5. Targeted inhibition of NRF2 reduces the invasive and metastatic ability of HIP1 depleted lung cancer cells.
Prasad P; Chongtham J; Tripathi SC; Ganguly NK; Mittal SA; Srivastava T
Biochem Biophys Res Commun; 2024 Nov; 733():150676. PubMed ID: 39303527
[TBL] [Abstract] [Full Text] [Related]
6. Oncogenic Mutant p53 Sensitizes Non-small cell lung cancer cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis.
Chougoni KK; Neely V; Ding B; Oduah E; Lam VT; Hu B; Koblinski JE; Windle BE; Palit Deb S; Deb S; Nieva JJ; Radhakrishnan SK; Harada H; Grossman SR
Cancer Res Commun; 2024 Oct; 4(10):2685-2698. PubMed ID: 39302104
[TBL] [Abstract] [Full Text] [Related]
7. The expression of YAP1 and other transcription factors contributes to lineage plasticity in combined small cell lung carcinoma.
Jimbo N; Ohbayashi C; Fujii T; Takeda M; Mitsui S; Tanaka Y; Itoh T; Maniwa Y
J Pathol Clin Res; 2024 Sep; 10(5):e70001. PubMed ID: 39283755
[TBL] [Abstract] [Full Text] [Related]
8. Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism of Protopanaxadiol Triphenylphosphate Derivative in Non-small-cell lung cancer.
Han L; Bian X; Ma X; Ren T; Li Y; Huang L; Tang Z; Gao L; Chang S; Sun X
Molecules; 2024 Sep; 29(17):. PubMed ID: 39275122
[TBL] [Abstract] [Full Text] [Related]
9. Decoding potential targets and pharmacologic mechanisms of curcumin in treating non-small cell lung carcinoma via bioinformatics and molecular docking.
Li J; Zhang Z; Zhao J; Liu S; Feng C; Deng H; Liu D; Zeng J; Yu Q; Zhou D; Zhu M; Liu Y
Braz J Med Biol Res; 2024; 57():e13550. PubMed ID: 39258670
[TBL] [Abstract] [Full Text] [Related]
10. Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
Gu G; Liu C; Zhu X; Yang Y; Song S; Zhao Y; Sun G
J Cancer Res Clin Oncol; 2024 Sep; 150(9):413. PubMed ID: 39244518
[TBL] [Abstract] [Full Text] [Related]
11. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance.
Montégut L; Liu P; Zhao L; Pérez-Lanzón M; Chen H; Mao M; Zhang S; Derosa L; Naour JL; Lambertucci F; Mingoia S; Nogueira-Recalde U; Mena-Osuna R; Herranz-Montoya I; Djouder N; Baulande S; Pan H; Joseph A; Messaoudene M; Routy B; Fidelle M; Ahmed TB; Caron O; Busson P; Boulate D; Deschasaux-Tanguy M; Arnault N; Pol JG; Piaggio E; Touvier M; Zitvogel L; Delaloge S; Martins I; Kroemer G
Mol Cancer; 2024 Sep; 23(1):187. PubMed ID: 39242519
[TBL] [Abstract] [Full Text] [Related]
12. Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
Marks JA; Gandhi N; Halmos B; Marmarelis ME; Yeon Kim S; Bazhenova L; Ramalingam SS; Xiu J; Walker P; Oberley MJ; Ma PC; Liu SV
Lung Cancer; 2024 Oct; 196():107935. PubMed ID: 39241297
[TBL] [Abstract] [Full Text] [Related]
13. Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view.
Meinag FE; Fatahi M; Vahedian V; Maroufi NF; Mosayyebi B; Ahmadi E; Rahmati M
Funct Integr Genomics; 2024 Sep; 24(5):150. PubMed ID: 39222264
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of ULK1/2 and KRAS
Ghazi PC; O'Toole KT; Srinivas Boggaram S; Scherzer MT; Silvis MR; Zhang Y; Bogdan M; Smith BD; Lozano G; Flynn DL; Snyder EL; Kinsey CG; McMahon M
Elife; 2024 Aug; 13():. PubMed ID: 39213022
[TBL] [Abstract] [Full Text] [Related]
15. Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-small-cell lung cancer-A Single-Center Experience.
Kuang S; Chen K; Sayal S; Prabahan G; Rabey MR; Le LW; Seto A; Shepherd FA; Liu G; Bradbury P; Sacher AG; Law JH; Sabatini P; Stockley TL; Tsao MS; Leighl NB
Curr Oncol; 2024 Aug; 31(8):4476-4485. PubMed ID: 39195317
[TBL] [Abstract] [Full Text] [Related]
16. [Clinical characteristics and prognostic analysis of thoracic SMARCA4-deficient undifferentiated tumor].
Wang XT; Kang Y; Wang HY; Shi WW; Xiao Y; Liu YH; Si JM; Li SL; Jin JJ
Zhonghua Yi Xue Za Zhi; 2024 Sep; 104(34):3214-3220. PubMed ID: 39193606
[No Abstract] [Full Text] [Related]
17. Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy.
Zheng X; Zhou L; Shi H; An J; Xu W; Ding X; Hua Y; Shi W; Li X
Thorac Cancer; 2024 Oct; 15(28):2029-2037. PubMed ID: 39189250
[TBL] [Abstract] [Full Text] [Related]
18. Two-polarized roles of transcription factor FOSB in lung cancer progression and prognosis: dependent on p53 status.
Zhang H; Zhang G; Xiao M; Cui S; Jin C; Yang J; Wu S; Lu X
J Exp Clin Cancer Res; 2024 Aug; 43(1):237. PubMed ID: 39164746
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.
Jiang Y; Xie J; Cheng Q; Cai Z; Xu K; Lu W; Wang F; Wu X; Song Y; Lv T; Zhan P
Int Immunopharmacol; 2024 Nov; 141():112901. PubMed ID: 39151386
[TBL] [Abstract] [Full Text] [Related]
20. YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.
Stewart CA; Diao L; Xi Y; Wang R; Ramkumar K; Serrano AG; Tanimoto A; Rodriguez BL; Morris BB; Shen L; Zhang B; Yang Y; Hamad SH; Cardnell RJ; Duarte A; Sahu M; Novegil VY; Weissman BE; Frumovitz M; Kalhor N; Solis Soto L; da Rocha P; Vokes N; Gibbons DL; Wang J; Heymach JV; Glisson B; Byers LA; Gay CM
Clin Cancer Res; 2024 Oct; 30(20):4743-4754. PubMed ID: 39150543
[TBL] [Abstract] [Full Text] [Related]
[Next]
